Physician profile
Wesley Gillette
NPI 1811552045
$1,056.72
in general payments reported to CMS, 2019-2025
13 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $125 · 2023: $80.37 · 2024: $350 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $207.36 | 2024-2025 | Acthar |
| Alcon Vision LLC | $179.11 | 2021-2024 | Constellation |
| Bausch & Lomb Americas INC. | $149.51 | 2022-2025 | Visudyne, Xipere |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.53 | 2021 | |
| Glaukos Corporation | $111.43 | 2021 | |
| Apellis Pharmaceuticals, INC. | $89.90 | 2023-2024 | Syfovre |
| New World Medical,INC. | $57.92 | 2023 | |
| Harrow Eye, LLC | $52.36 | 2024-2025 | Iheezo |
| Biogen, INC. | $22.71 | 2024 | Byooviz |
| Coherus Oncology, INC. | $20.70 | 2024 | |
| Genentech USA, INC. | $17.76 | 2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $15.62 | 2025 | Eylea Hd |
| Abbvie INC. | $14.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Gillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.